Plant derived diarylheptanoids as Wnt/β-catenin pathway inhibitors

Journal of Pharmacognosy & Natural Products

ISSN: 2472-0992

Open Access

Plant derived diarylheptanoids as Wnt/β-catenin pathway inhibitors

International Conference and Exhibition on Marine Drugs and Natural Products

July 25-27, 2016 Melbourne, Australia

Jae-Ha Ryu

Sookmyung Womens University, Republic of Korea

Scientific Tracks Abstracts: J Pharmacogn Nat Prod

Abstract :

The Wnt/?²-catenin signaling pathway plays a primary role in the differentiation, proliferation, and function of many cells but disruption of the pathway is involved in cancer development including colon cancer. Colorectal cancer is the third most common cancer in males and the second most common cancer in females, accounting for approximately 10% of all cancer-related deaths. Inhibiting the Wnt/?²-catenin pathway can be a good strategy for chemoprevention and treatment of colorectal cancer. While screening for Wnt/?²-catenin pathway inhibitors from medicinal plants, we found that (E)-7-(4-hydroxy-3-methoxyphenyl)-1-phenylhept-4- en-3-one (compound 1), among six diarylheptanoids from lesser galangal (Alpinia officinarum), most potently suppressed Wnt3ainduced ?²-catenin/Tcell factor activity. Moreover, compound 1 suppressed proliferation of colon cancer cells by inhibiting ?²-catenin translocation to the nucleus by disrupting the ?²-catenin/galectin-3 complex. Furthermore, a structureâ??activity realtionship study implicated that the enone group in the linker is critical and the hydroxy substituent on the aromatic ring is generally preferred for activity. Our findings suggest that diarylheptanoids from lesser galangal exerts anticolon cancer activity by down regulating the Wnt/?²-catenin pathway. Bioactive diarylheptanoids and the basic understanding of their structureâ??activity relationship could be utilized to develop potential candidates for ?²-catenin-targeted cancer treatment.

Biography :

Jae-Ha Ryu has completed his PhD at the College of Pharmacy, Seoul National University, Korea in 1989 and Post-doctoral studies from National Institute of Health, Maryland, USA. He got academic postion in 1992 at College of Pharmacy, Sookmyung Women’s University, Seoul Korea. He is the Director of Research Center for Cell Fate Control (Medical Research Center). His main research interest is to suggest leading compounds from medicinal plants for drug development, especially for the treatment of cancer and various metabolic diseases. He has published 150 papers in reputed journals.


arrow_upward arrow_upward